Click Therapeutics

Click Therapeutics develops software that provides prescription digital therapeutics (PDTs) for individuals diagnosed with mental health and chronic conditions. It's only nonprescription therapeutic, a smoking cessation product called Ckickotine, is commercially available and clinically validated despite not requiring FDA approval. 

The company leverages adaptive data science and machine learning algorithms to personalize content and ensure user engagement. Click’s programs attempt to change individual behavior through cognitive and neurobehavioral mechanisms and can be used independently or in conjunction with biomedical treatments. Users can download the app after being prescribed by a physician and activate it using a pharmacist-issued activation code. The treatments (missions for users) are usually between eight and 12 weeks long, and patients can interact with physicians during or after completing therapy. 

In March 2024, the company, in collaboration with Otsuka Pharmaceutical, launched Rejoyn, the first FDA-cleared prescription digital therapeutic for the adjunctive treatment of major depressive disorder (MDD) symptoms in adults aged 22 and older who are on antidepressant medication. Rejoyn utilizes cognitive emotional brain training exercises and cognitive behavioral therapy to help reduce depression symptoms.

Additionally, as of September 2024, the company had several PDTs in the pipeline across a variety of therapeutic areas that were still in the development stage, including insomnia, schizophrenia, migraines, acute coronary syndrome, overactive bladder, obesity, and chronic lower back pain. The company's pipeline includes CT-155, a PDT for treating negative symptoms of schizophrenia, which received FDA Breakthrough Device designation in January 2024. Click is also developing CT-132, a PDT for episodic migraine prevention that received FDA Breakthrough Device designation in December 2022. 

In May 2024, Click acquired assets from Better Therapeutics, including AspyreRx, an FDA-authorized PDT for type two diabetes, to accelerate its development initiatives in obesity and cardiometabolic diseases.

Key customers and partnerships

Click partnered with Magellan Health for clinical coaching and pharmacy benefits management in 2016. Additionally, the company has collaborated with Otsuka (December 2018) in a deal worth USD 302 million to develop and commercialize a PDT for the treatment of MDD, as well as a partnership with Boehringer Ingelheim (September 2020) to develop and commercialize a PDT to aid in the treatment of schizophrenia.

Furthermore, in September 2023, Click initiated a partnership with Indivior to develop a prescription digital therapeutic for opioid use disorder.